Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib + Atezolizumab in Relapsed/Refractory FLT3+ AML
NCT03730012Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2019
- Primary completion
- May 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of gilteritinib in acute myeloid leukemia (AML), sponsored by Astellas Pharma. Started Jun 2019; status: completed.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03730012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03730012.